### Comment:
'In April 2018, Omeros reported new results in patients with HSCT-TMA from the ongoing OMS721 Phase 2 study. The analysis of 100-day mortality, an important endpoint previously used as an approval endpoint in another condition related to HSCT, showed that OMS721-treated patients had improved survival relative to the historical control 53% vs 10%' 


### REPLY:
Greg sounds pretty positive about 721 getting approval possibly this year. I struggle to keep up with all the different indications it's being studied for. All it needs is one to be approved I guess, then it's a moon trip for us. Nice to see the SP staying above 20 fit a while now too.

### END.